Transcriptional regulation of miR-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1

Molecular Cancer Research

Volumn 14, Issue 3, 2016, Pages 267-277

  Kent, Oliver A ^a   Mendell, Joshua T ^b,c   Rottapel, Robert ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MICRORNA 31; MITOGEN ACTIVATED PROTEIN KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR ELK 1; ELK1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; KRAS PROTEIN, HUMAN; MICRORNA; MIRN31 MICRORNA, HUMAN; PROTEIN P21; RASA1 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CELL MIGRATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE TARGETING; MOLECULAR INTERACTION; PANCREATIC CANCER CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RASA1 GENE; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR XENOGRAFT; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HUMAN; METABOLISM; MUTATION; PANCREAS TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MUTATION; P120 GTPASE ACTIVATING PROTEIN; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84962323908     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0456     Document Type: Article

References (42)

1. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
3. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217-22.
4. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447: 1130-4.
5. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, et al. Repression of the miR-143/145 cluster by oncogenic RAS initiates a tumor-promoting feed-forward pathway. Genes Dev 2010;24:2754-9.
6. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157-88.
7. Barbacid M. RAS genes. Annu Rev Biochem 1987;56:779-827.
8. Macara IG, Lounsbury KM, Richards SA, McKiernan C, Bar-Sagi D. The RAS superfamily of GTPases. FASEB J 1996;5:625-30.
9. Prior IA, Lewis PD, Mattos C. A comprehensive survey of RAS mutations in cancer. Cancer Res 2012;72:2457-67.
10. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28:1385-92.
11. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7microRNAreduces tumor growthinmousemodelsoflung cancer. Cell Cycle 2008;7:759-64.
12. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocar-cinoma by targeting KRAS. Carcinogenesis 2010;31:1726-33.
13. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, et al. Modulation of K-RAS-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18:282-93.
14. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2012;32:2576-85.
15. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57:1420-30.
16. Kent OA, Mullendore M, Wentzel EA, Lopez-Romero P, Tan AC, Alvarez H, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009;8:2013-24.
17. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. KRAS promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007;67:2098-106.
18. Geissmann Q. Open CFU, anewfree and open-sourcesoftwaretocountcell colonies and other circular objects. PLoS ONE 2013;8:e54072.
19. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003;301:1038-44.
20. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8.
21. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004;10:1957-66.
22. Chang TC, Pertea M, Lee S, Salzberg SL, Mendell JT. Genome-wide annotation of microRNA primary transcript structures reveals novel regulatory mechanisms. Genome Res 2015;25:1401-9.
23. Lenhard B, Sandelin A, Mendoza L, Engstrom P, Jareborg N, Wasserman WW. Identification of conserved regulatory elements by comparative genome analysis. J Biol Chem 2013;288:9508-18.
24. Koehler JA, Moran MF. Regulation of extracellular signal-regulated kinase activity by p120 RASGAP does not involve its pleckstrin homology or calcium-dependent lipid binding domains but does require these domains to regulate cell proliferation. Cell Growth Differ 2001;12:551-61.
25. Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, Allain B, Tocca-fondi M, Garbay C, et al. p120-RAS GTPase activating protein (RASGAP): a multi-interacting protein in downstream signaling. Biochimie 2009;91:320-8.
26. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med 2013;6:1265-70.
27. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colo-rectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol 2013;288:9508-18.
28. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148: 349-61.
29. Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, et al. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analy-sis, experimental validation and clinical significance. J Exp Clin Cancer Res 2013;32:71-85.
30. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;6:4442-52.
31. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. Micro RNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309.
32. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5:29-39.
33. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014;35:776-83.
34. Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 2015;356:404-9.
35. Laurila EM, Sandstrom S, Rantanen LM, Autio R, Kallioniemi A. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 2012;51:557-68.
36. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge onTIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 2010;285:35293-302.
37. Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, et al. Micro RNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 2013;19:5423-33.
38. Bar-Sagi D, Hall A. RAS and Rho GTPases: a family reunion. Cell 2000; 103:227-38.
39. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 2004;206:181-91.
40. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2: 133-42.
41. Cullis J, Meiri D, Sandi MJ, Radulovich N, Kent OA, Medrano M, et al. The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. Cancer Cell 2014;25:181-95.
42. Gong B, Liu W, Nie W, Li D, Xie Z, Liu C, et al. MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways. World J Gastroenterol 2015;21:1488-97.